Publication
Abstract
Realization of a part of a clinical trial called multicenter, randomized study, double-blind, placebo-controlled, phase III, with the administration of Tarceva (R) (erlotinib) after complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA NSCLC who are EGFR positive